New daily pill hopes to control advanced cancers

NCT ID NCT06395519

Recruiting now Disease control Sponsor: 858 Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselves. The main goals are to find a safe dose and see if the drug can help control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ETX-19477 (a daily oral pill that blocks a protein called PARG to potentially stop cancer cells from repairing themselves)
What this could lead to: If this works, it could offer a new daily treatment option for people with advanced solid tumors, especially those with BRCA mutations, helping to control their cancer.
What could go wrong: This is an early Phase 1/2 trial with only 120 participants, so it's too soon to know if the drug is effective. It may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition breast cancer breast neoplasm Carcinoma, Ovarian Epithelial castration-resistant prostate carcinoma colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm estrogen-receptor positive breast cancer gastric cancer gastric neoplasm metastatic malignant neoplasm neoplasm ovarian cancer ovarian carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS BRCA MUTATION BRCA1 MUTATION BRCA2 MUTATION BREAST CANCER CASTRATE RESISTANT PROSTATE CANCER COLORECTAL CANCER ENDOMETRIAL CANCER EPITHELIAL OVARIAN CANCER ERΑ+ BREAST CANCER GASTRIC CANCER OVARIAN CANCER PROSTATE CANCER

Contacts and locations

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
START Center for Cancer Care - Mountain Region
RECRUITING

Salt Lake City, Utah, 84112, United States
Stefanie Spielman Comprehensive Breast Center
RECRUITING

Columbus, Ohio, 43212, United States
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Yale University, Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.